Skip to main content

Demyelinating diseases

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Page 1 of 7

  1. In patients with multiple sclerosis (MS), the disease’s complications and manifestations affect a person’s ability to function normally and leads to further disruptions in their education, family life, job opp...

    Authors: Atefeh Homayuni, Sedigheh Abedini, Zahra Hosseini, Masoud Etemadifar and Amin Ghanbarnejad

    Citation: BMC Neurology 2021 21:193

    Content type: Research article

    Published on:

  2. In this study, we aimed to determine the risk association between vitamin D binding protein (VDBP) polymorphism in patients with multiple sclerosis (MS) in a MS biobank and the difference in VDBP serum levels ...

    Authors: Zhila Maghbooli, Abolfazl Omidifar, Tarlan Varzandi, Tayebeh Salehnezhad and Mohammad Ali Sahraian

    Citation: BMC Neurology 2021 21:168

    Content type: Research article

    Published on:

  3. Neuromyelitis optica spectrum disorder (NMOSD) is associated with inflammatory mediators that may also trigger downstream signaling pathways leading to reduce insulin sensitivity.

    Authors: Zhila Maghbooli, Abdorreza Naser Moghadasi, Nasim Rezaeimanesh, Abolfazl Omidifar, Tarlan Varzandi and Mohammad Ali Sahraian

    Citation: BMC Neurology 2021 21:167

    Content type: Research article

    Published on:

  4. Self-efficacy concerns individuals’ beliefs in their capability to exercise control in specific situations and complete tasks successfully. In people with multiple sclerosis (PwMS), self-efficacy has been asso...

    Authors: Barbara Seebacher, Roger J. Mills, Markus Reindl, Laura Zamarian, Simone Kircher, Christian Brenneis, Rainer Ehling and Florian Deisenhammer

    Citation: BMC Neurology 2021 21:163

    Content type: Research article

    Published on:

  5. Progressive multifocal leukoencephalopathy (PML) can rarely occur in Multiple Sclerosis (MS) patients undergoing dimethyl fumarate (DMF) treatment. Our case stresses the limits of current diagnostic and strati...

    Authors: Elena Augusta Vola, Maria Petracca, Sirio Cocozza, Marcello De Angelis, Antonio Carotenuto, Giuseppe Pontillo, Vincenzo Brescia Morra, Enrico Tedeschi and Roberta Lanzillo

    Citation: BMC Neurology 2021 21:146

    Content type: Case report

    Published on:

  6. Socioeconomic factors may be involved in risk of multiple sclerosis (MS), either indirectly or as confounding factors. In this study two comprehensive indicators reflecting socioeconomic differences, including...

    Authors: Vahid Kazemi Moghaddam, Aisha S. Dickerson, Edris Bazrafshan, Seyedeh Nahid Seyedhasani, Fereshteh Najafi, Mostafa Hadei, Jalil Momeni, Ghasem Moradi and Mohammad Sarmadi

    Citation: BMC Neurology 2021 21:145

    Content type: Research article

    Published on:

  7. Though adherence to disease-modifying therapies (DMTs) among persons with multiple sclerosis (PwMS) varies and is often below 80%, only few prospective studies on adherence examined predictors beyond demograph...

    Authors: Efrat Neter, Lea Glass-Marmor, Anat Wolkowitz, Idit Lavi and Ariel Miller

    Citation: BMC Neurology 2021 21:136

    Content type: Research article

    Published on:

  8. Bickerstaff’s brainstem encephalitis (BBE) and Fisher syndrome (FS) are immune-mediated diseases associated with anti-ganglioside antibodies, specifically the anti-GQ1b IgG antibody. These two diseases potenti...

    Authors: Hirokazu Natsui, Makoto Takahashi, Kentaro Nanatsue, Sakiko Itaya, Keisuke Abe, Akira Inaba and Satoshi Orimo

    Citation: BMC Neurology 2021 21:130

    Content type: Case report

    Published on:

  9. Neuromyelitis optica spectrum disorders (NMOSD), a group of autoimmune neurological diseases, involve the optic nerve, spinal cord, and brain. Meningitis is rarely reported as the primary clinical manifestatio...

    Authors: Chenyang Zhang, Kang Zhang, Bing Chen, Jiao Yin, Miaomiao Dong, Yixin Qin and Xiao Yang

    Citation: BMC Neurology 2021 21:109

    Content type: Case report

    Published on:

  10. Persons with multiple sclerosis (PwMS) often have reduced aerobic capacity and report fatigue as the most disabling symptom impacting their health-related quality of life (HRQoL). A multidisciplinary rehabilit...

    Authors: Nadine Patt, Jan Kool, Ruth Hersche, Max Oberste, David Walzik, Niklas Joisten, Daniel Caminada, Francesca Ferrara, Roman Gonzenbach, Claudio Renato Nigg, Christian Philipp Kamm, Philipp Zimmer and Jens Bansi

    Citation: BMC Neurology 2021 21:65

    Content type: Study protocol

    Published on:

  11. Fingolimod is a S1P1 receptor modulator that prevents activated lymphocyte egress from lymphoid tissues causing lymphopenia, mainly affecting CD4+ T lymphocytes. Withdrawal from fingolimod can be followed by seve...

    Authors: Silvia Delgado, Jeffrey Hernandez, Leticia Tornes and Kottil Rammohan

    Citation: BMC Neurology 2021 21:48

    Content type: Case report

    Published on:

  12. Early stage neuromyelitis optica spectrum disorders (NMOSD) with non-opticospinal manifestations as initial symptoms are easily misdiagnosed; however, data on the full symptom profile are limited. Moreover, th...

    Authors: Rui Li, Danli Lu, Hao Li, Yuge Wang, Yaqing Shu, Yanyu Chang, Xiaobo Sun, Zhengqi Lu, Wei Qiu and Zhi Yang

    Citation: BMC Neurology 2021 21:35

    Content type: Research article

    Published on:

  13. Currently, myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis (MOG-EM) is regarded as an independent inflammatory demyelinating disease. Magnetic resonance imaging (MRI) abnormalities o...

    Authors: Weibing Shen, Yaner Zhang, Chenguang Zhou and Yaoyao Shen

    Citation: BMC Neurology 2021 21:10

    Content type: Case report

    Published on:

  14. Glial fibrillary acidic protein (GFAP) autoimmune astrocytopathy is characterized by GFAP autoantibody positive encephalitis, meningoencephalitis or meningoencephalomyelitis. The initial clinical presentation ...

    Authors: Han Wang, Jerome H. Chin, Bo-yan Fang, Xi Chen, Ai-lin Zhao, Hai-tao Ren and Hong-zhi Guan

    Citation: BMC Neurology 2020 20:443

    Content type: Case report

    Published on:

  15. Nine oral disease-modifying therapies (DMTs) have been approved for the treatment of multiple sclerosis (MS) in the United States. Few studies have examined self-reported quality of life (QoL) and functional s...

    Authors: Tamela Stuchiner, Lindsay Lucas, Elizabeth Baraban, Kateri J. Spinelli, Chiayi Chen, Alden Smith, Lobat Hashemi and Stanley Cohan

    Citation: BMC Neurology 2020 20:439

    Content type: Research article

    Published on:

  16. Symptoms arising from vestibular system dysfunction are observed in 49–59% of people with Multiple Sclerosis (MS). Symptoms may include vertigo, dizziness and/or imbalance. These impact on functional ability, ...

    Authors: J. Marsden, M. Pavlou, R. Dennett, A. Gibbon, R. Knight-Lozano, L. Jeu, C. Flavell, J. Freeman, D. E. Bamiou, C. Harris, A. Hawton, E. Goodwin, B. Jones and S. Creanor

    Citation: BMC Neurology 2020 20:430

    Content type: Study protocol

    Published on:

  17. Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a severe autoimmune encephalitis mediated by anti-NMDA receptor antibodies. Brain MRI manifestations vary and are non-specific. If there are any lesion...

    Authors: Rupan Gao, Xiang Zhang, Abhijeet Kumar Bhekharee and Yue Zhang

    Citation: BMC Neurology 2020 20:421

    Content type: Case report

    Published on:

  18. Baló’s Concentric Sclerosis (BCS) is a rare heterogeneous demyelinating disease with a variety of phenotypes on Magnetic Resonance Imaging (MRI). Existing literature lacks data especially on the therapeutic ap...

    Authors: D. Tzanetakos, A. G. Vakrakou, J. S. Tzartos, G. Velonakis, M. E. Evangelopoulos, M. Anagnostouli, G. Koutsis, E. Dardiotis, E. Karavasilis, P. Toulas, L. Stefanis and C. Kilidireas

    Citation: BMC Neurology 2020 20:400

    Content type: Research article

    Published on:

  19. Multiple sclerosis (MS) is a neurological disease that is caused by an autoimmune response that results in the neuron’s demyelination in the central nervous system. The exact etiology of MS is not clear; howev...

    Authors: Raid M. Kofahi, Hassan M. Kofahi, Suhib Sabaheen, Majdi Al Qawasmeh, Aiman Momani, Ahmed Yassin, Kefah Alhayk and Khalid El-Salem

    Citation: BMC Neurology 2020 20:397

    Content type: Research article

    Published on:

  20. Hepatitis E infection affects over 20 million people worldwide. Reports of neurological manifestations are largely limited to the peripheral nervous system. We report a middle-aged genotype 3c male patient wit...

    Authors: Jan Rahmig, Arne Grey, Marco Berning, Jochen Schaefer, Martin Lesser, Heinz Reichmann, Volker Puetz, Kristian Barlinn and Timo Siepmann

    Citation: BMC Neurology 2020 20:391

    Content type: Case report

    Published on:

  21. In this pooled, post hoc analysis of a phase 2 trial and the phase 3 TEMSO, TOWER, and TENERE clinical trials, long-term efficacy and safety of teriflunomide were assessed in subgroups of patients with relapsi...

    Authors: Giancarlo Comi, Mark S. Freedman, José E. Meca-Lallana, Patrick Vermersch, Byoung Joon Kim, Alexander Parajeles, Keith R. Edwards, Ralf Gold, Houari Korideck, Jeffrey Chavin, Elizabeth M. Poole and Patricia K. Coyle

    Citation: BMC Neurology 2020 20:364

    Content type: Research article

    Published on:

  22. Susac syndrome (SuS) is a rare condition characterized by a clinical triad of sensorineural hearing loss, branch artery occlusion and encephalopathy. This study reports an increased incidence of SuS in Israel....

    Authors: A. Wilf-Yarkoni, O. Elkayam, O. Aizenstein, Y. Oron, V. Furer, D. Zur, M. Goldstein, D. Barequet, H. Hallevi, A. Karni, Z. Habot-Wilner and K. Regev

    Citation: BMC Neurology 2020 20:332

    Content type: Research article

    Published on:

  23. Nonadherence to disease-modifying drugs (DMDs) for multiple sclerosis (MS) is associated with poorer clinical outcomes, including higher rates of relapse and disease progression, and higher medical resource us...

    Authors: Jacqueline A. Nicholas, Natalie C. Edwards, Roger A. Edwards, Anna Dellarole, Megan Grosso and Amy L. Phillips

    Citation: BMC Neurology 2020 20:281

    Content type: Research article

    Published on:

  24. Several studies have reported the association between polymorphisms in Matrix metalloproteinases (MMPs) gene family and risk of Multiple sclerosis (MS). However, the results have been inconsistent and inconclu...

    Authors: Mina Mohammadhosayni, Arezou Khosrojerdi, Keivan Lorian, Saeed Aslani, Danyal Imani, Bahman Razi, Farhad Babaie and Shahram Torkamandi

    Citation: BMC Neurology 2020 20:218

    Content type: Research article

    Published on:

  25. A high multiple sclerosis activity while on alemtuzumab is rather uncommon compared to moderate-efficacy drugs. The purpose of this case report is to present a case of a 37-year-old female patient with bronchi...

    Authors: Martin Vališ, Pavel Ryška, Simona Halúsková, Blanka Klímová and Zbyšek Pavelek

    Citation: BMC Neurology 2020 20:202

    Content type: Case report

    Published on:

  26. Stress cardiomyopathy (Takotsubo cardiomyopathy) is very rare in the central nervous system (CNS) demyelinating disorders. Although this dysfunction of the heart-brain axis has been reported in several case se...

    Authors: Sungsik An, Hyeo-il Ma, Jooyeon Song, Hong-Mi Choi and Young Eun Kim

    Citation: BMC Neurology 2020 20:201

    Content type: Case report

    Published on:

  27. The prevalence of Multiple Sclerosis (MS) has been increasing worldwide and the north–south gradient of prevalence may be disappearing in the Northern hemisphere. The few previous prevalence studies performed ...

    Authors: Mariana Branco, Ivânia Alves, Ana Martins da Silva, Joaquim Pinheiro, Maria José Sá, Inês Correia, Lívia Sousa, Eva Brandão, Carlos Veira, Bernardo Gomes and Luis Ruano

    Citation: BMC Neurology 2020 20:195

    Content type: Research article

    Published on:

  28. Cognitive impairment is common in patients with multiple sclerosis (MS). Accurate and repeatable measures of cognition have the potential to be used as markers of disease activity.

    Authors: Seyed-Mahdi Khaligh-Razavi, Maryam Sadeghi, Mahdiyeh Khanbagi, Chris Kalafatis and Seyed Massood Nabavi

    Citation: BMC Neurology 2020 20:193

    Content type: Research article

    Published on:

  29. Diverse mechanisms including infections, autoimmune inflammatory reactions, neoplasms, and degeneration are involved in the central nervous system in cases of acquired immune deficiency syndrome. In such cases...

    Authors: Mayu Ishiguro, Yuji Ueno, Yuta Ishiguro, Masashi Takanashi, Kenji Murai, Guillaume Taieb, Kensuke Daida, Akimitsu Suda, Kazumasa Yokoyama, Toshio Naito and Nobutaka Hattori

    Citation: BMC Neurology 2020 20:179

    Content type: Case report

    Published on:

  30. Neurodegeneration, rather than inflammation, plays a key role in the progressive phase of multiple sclerosis (MS). Current disease modifying treatment options for people with progressive MS (PMS) do not specif...

    Authors: A. S. Gravesteijn, H. Beckerman, B. A. de Jong, H. E. Hulst and V. de Groot

    Citation: BMC Neurology 2020 20:177

    Content type: Study protocol

    Published on:

  31. Multiple sclerosis (MS) is a chronic immune mediated disease and the progressive phase appears to have significant neurodegenerative mechanisms. The classification of the course of progressive MS (PMS) has bee...

    Authors: Ethel Ciampi, Reinaldo Uribe-San-Martin, Claudia Cárcamo, Juan Pablo Cruz, Ana Reyes, Diego Reyes, Carmen Pinto, Macarena Vásquez, Rafael A. Burgos and Juan Hancke

    Citation: BMC Neurology 2020 20:173

    Content type: Research article

    Published on:

  32. The epidemiological characteristics of multiple sclerosis (MS) have been investigated in various studies, which have revealed that the prevalence of MS varies across countries. The present study was conducted ...

    Authors: Amir Almasi-Hashiani, Mohammad Ali Sahraian and Sharareh Eskandarieh

    Citation: BMC Neurology 2020 20:169

    Content type: Research article

    Published on:

  33. Research is needed to examine differences in multiple sclerosis (MS) prevalence by race-ethnicity. The goal of this study was to quantify MS prevalence in a health care system in Northern California and examin...

    Authors: Robert J. Romanelli, Qiwen Huang, Joseph Lacy, Lobat Hashemi, Alana Wong and Alden Smith

    Citation: BMC Neurology 2020 20:163

    Content type: Research article

    Published on:

  34. Fingolimod (Gilenya®), a first-in-class sphingosine-1-phosphate receptor modulator is approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod-induced selective immunosuppression leads ...

    Authors: Tobias Wienemann, Ann-Kristin Müller, Colin MacKenzie, Carina Bielor, Vivien Weyers, Orhan Aktas, Hans-Peter Hartung and David Kremer

    Citation: BMC Neurology 2020 20:158

    Content type: Case report

    Published on:

  35. Evoked potentials (EPs) are a measure of the conductivity of the central nervous system. They are used to monitor disease progression of multiple sclerosis patients. Previous studies only extracted a few varia...

    Authors: Jan Yperman, Thijs Becker, Dirk Valkenborg, Veronica Popescu, Niels Hellings, Bart Van Wijmeersch and Liesbet M. Peeters

    Citation: BMC Neurology 2020 20:105

    Content type: Research Article

    Published on:

  36. Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A highly effective drug not only for relapsing but also for progressive forms of MS with a favorable safety profile is needed to f...

    Authors: Petra Dirks, Vera Zingler, Jost Leemhuis, Heike Berthold, Stefanie Hieke-Schulz, David Wormser and Tjalf Ziemssen

    Citation: BMC Neurology 2020 20:95

    Content type: Study protocol

    Published on:

  37. Neuroprotection and promotion of remyelination represent important therapeutic gaps in multiple sclerosis (MS). Acute optic neuritis (ON) is a frequent MS manifestation. Based on the presence and properties of...

    Authors: Christian Albert, Janine Mikolajczak, Anja Liekfeld, Sophie K. Piper, Michael Scheel, Hanna G. Zimmermann, Claus Nowak, Jan Dörr, Judith Bellmann-Strobl, Claudia Chien, Alexander U. Brandt, Friedemann Paul and Olaf Hoffmann

    Citation: BMC Neurology 2020 20:75

    Content type: Research article

    Published on:

  38. Genetic and environmental factors seem to have etiologic roles in multiple sclerosis (MS). Kuwait is regarded as medium to high risk country for MS. However, there is a paucity of published data on the risk fa...

    Authors: Hadeel El-Muzaini, Saeed Akhtar and Raed Alroughani

    Citation: BMC Neurology 2020 20:64

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Neurology 2020 20:306

  39. Information of Previous studies on the prevalence of MS, including our study conducted 12 years ago, used to shape global prevalence map of MS. According to those results, Iran placed in medium-prevalence MS r...

    Authors: Seyed Mohammad Baghbanian, Hamed Cheraghmakani, Reza HabibiSaravi, Arash Azar and Fariba Ghasemihamedani

    Citation: BMC Neurology 2020 20:52

    Content type: Research article

    Published on:

Annual Journal Metrics